HIGHLIGHTS
SUMMARY
The efficacy of nelfinavir treatment against SARS-CoV-2 has been also tested in_vivo by Foo CS et_al by monitoring hamster infection. Different in_vitro and in_vivo studies demonstrated the anti-SARS-CoV-2 activity of molnupiravir. Cox et_al, using an in_vitro model similar to ours (but with a higher viral dose of infection of 0.1 MOI instead of 0.01), found an EC50 and EC90 of 3.4 µM and 5.4 µM, respectively. Molnupiravir was also demonstrated to reduce the viral titer of SARS-CoV-2 in other in_vivo models. The study . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.